Literature DB >> 6626259

Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine.

S P Bagchi.   

Abstract

This study has examined the effects on synaptosomal (P2) dopamine of interactions of phencyclidine and some other stimulants with tetrabenazine and reserpine. Tetrabenazine and reserpine both enhanced the spontaneous synaptosomal release of [14C]dopamine and inhibited its formation from [14C]phenylalanine. The [14C]dopamine formation increases induced by phencyclidine and amfonelic acid, however, were affected differentially by coadditions of tetrabenazine and reserpine. At the lower concentrations, tetrabenazine either did not affect or augmented the dopamine formation enhancements by the stimulants. Reserpine at all levels blocked the synthesis enhancements and revealed inhibitory effects of phencyclidine and amfonelic acid upon dopamine formation; only at the highest concentration did the action of tetrabenazine mimick that of reserpine. Amphetamine stimulation of dopamine formation was affected by tetrabenazine and reserpine alike; the stimulation was either maintained or enhanced. Ketamine did not affect dopamine formation either by itself, with tetrabenazine, or with reserpine. In summary, tetrabenazine and reserpine affected synaptosomal dopamine formation and release in a comparable manner, but intraneuronal dopaminergic actions of phencyclidine and also of amfonelic acid may be influenced differentially by these two releasing agents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626259     DOI: 10.1016/0006-2952(83)90388-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.

Authors:  Samuel Frank
Journal:  BMC Neurol       Date:  2009-12-18       Impact factor: 2.474

Review 3.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

5.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

Authors:  Samuel Frank
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

Review 6.  Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.

Authors:  Marissa Dean; Victor W Sung
Journal:  Drug Des Devel Ther       Date:  2018-02-15       Impact factor: 4.162

Review 7.  Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders.

Authors:  Adaze Bijou Enogieru; William Haylett; Donavon Charles Hiss; Soraya Bardien; Okobi Eko Ekpo
Journal:  Oxid Med Cell Longev       Date:  2018-06-27       Impact factor: 6.543

Review 8.  Synaptic pathology in Huntington's disease: Beyond the corticostriatal pathway.

Authors:  Joshua Barry; Minh T N Bui; Michael S Levine; Carlos Cepeda
Journal:  Neurobiol Dis       Date:  2021-11-27       Impact factor: 7.046

Review 9.  Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty.

Authors:  Alexandru Vasincu; Răzvan-Nicolae Rusu; Daniela-Carmen Ababei; Mădălina Larion; Walther Bild; Gabriela Dumitrița Stanciu; Carmen Solcan; Veronica Bild
Journal:  Biology (Basel)       Date:  2022-03-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.